| International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ... The lancet oncology 15 (12), e538-e548, 2014 | 5636 | 2014 |
| International uniform response criteria for multiple myeloma BGM Durie, JL Harousseau, JS Miguel, J Blade, B Barlogie, K Anderson, ... Leukemia 20 (9), 1467-1473, 2006 | 3560 | 2006 |
| Daratumumab, bortezomib, and dexamethasone for multiple myeloma A Palumbo, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, ... New England Journal of Medicine 375 (8), 754-766, 2016 | 1787 | 2016 |
| Elotuzumab therapy for relapsed or refractory multiple myeloma S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ... New England Journal of Medicine 373 (7), 621-631, 2015 | 1613 | 2015 |
| Continuous lenalidomide treatment for newly diagnosed multiple myeloma A Palumbo, R Hajek, M Delforge, M Kropff, MT Petrucci, J Catalano, ... New England Journal of Medicine 366 (19), 1759-1769, 2012 | 954 | 2012 |
| Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a … JF San-Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... The lancet oncology 15 (11), 1195-1206, 2014 | 940 | 2014 |
| Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a … M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ... The Lancet 394 (10214), 2096-2107, 2019 | 754* | 2019 |
| Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders AC Rawstron, A Orfao, M Beksac, L Bezdickova, R Brooimans, H Bumbea, ... haematologica 93 (3), 431-438, 2008 | 683 | 2008 |
| The shaping of modern human immune systems by multiregional admixture with archaic humans L Abi-Rached, MJ Jobin, S Kulkarni, A McWhinnie, K Dalva, L Gragert, ... Science 334 (6052), 89-94, 2011 | 620 | 2011 |
| Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3 M Dimopoulos, R Kyle, JP Fermand, SV Rajkumar, J San Miguel, ... Blood, The Journal of the American Society of Hematology 117 (18), 4701-4705, 2011 | 556 | 2011 |
| Daratumumab-based treatment for immunoglobulin light-chain amyloidosis E Kastritis, G Palladini, MC Minnema, AD Wechalekar, A Jaccard, HC Lee, ... New England Journal of Medicine 385 (1), 46-58, 2021 | 506 | 2021 |
| Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) A Palumbo, S Bringhen, H Ludwig, MA Dimopoulos, J Bladé, MV Mateos, ... Blood, The Journal of the American Society of Hematology 118 (17), 4519-4529, 2011 | 483 | 2011 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 478 | 2016 |
| European Myeloma Network guidelines for the management of multiple myeloma-related complications E Terpos, M Kleber, M Engelhardt, S Zweegman, F Gay, E Kastritis, ... haematologica 100 (10), 1254, 2015 | 451 | 2015 |
| International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma M Dimopoulos, E Terpos, RL Comenzo, P Tosi, M Beksac, O Sezer, ... Leukemia 23 (9), 1545-1556, 2009 | 417 | 2009 |
| Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label … PG Richardson, A Oriol, M Beksac, AM Liberati, M Galli, F Schjesvold, ... The Lancet Oncology 20 (6), 781-794, 2019 | 399 | 2019 |
| Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and … M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci, MA Dimopoulos, ... The Lancet Haematology 7 (6), e456-e468, 2020 | 381 | 2020 |
| Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials PM Fayers, A Palumbo, C Hulin, A Waage, P Wijermans, M Beksaç, ... Blood, The Journal of the American Society of Hematology 118 (5), 1239-1247, 2011 | 356 | 2011 |
| Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ... Leukemia 31 (11), 2443-2448, 2017 | 351 | 2017 |
| Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 … MA Dimopoulos, E Terpos, M Boccadoro, S Delimpasi, M Beksac, ... The Lancet Oncology 22 (6), 801-812, 2021 | 330 | 2021 |
Meletios Athanasios DimopoulosNational and Kapodistrian University of Athens, School of MedicineEmail được xác minh tại med.uoa.gr
